-
Mashup Score: 35
These data further support that ICI rechallenge should be discouraged in patients with advanced renal cell carcinoma. Furthermore, these data suggest that tivozanib monotherapy has efficacy in the post-ICI setting.
Source: www.thelancet.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 3
Tian Zhang: STAREV is open and enrolling UTSW Simmons Cancer Center / bladder cancer, cancer, cystectomy, enfortumab, Hematology, Neil Desai, OncoDaily,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: STAREV is open and enrolling @utswcancer Simmons Cancer Center - @TiansterZhang https://t.co/De8ZZSld7U #Health #Medicine…
-
-
Mashup Score: 2Smart Steps for Effective Real-World Care in RCC: Enhancing Outcomes in Advanced Disease - 4 month(s) ago
See the latest #RCC live event from @PeerView @montypal @tiansterzhang #IKCSNA24 #MedEd
Source: lrn.peerview.comCategories: General Medicine News, Hem/OncsTweet-
RT @QianJanieQin: Join us in person or #virtually at https://t.co/y0V8wz4fkY for a lively discussion with @TiansterZhang #Dr. Nazar Tannir…
-
-
Mashup Score: 2Smart Steps for Effective Real-World Care in RCC: Enhancing Outcomes in Advanced Disease - 4 month(s) ago
See the latest #RCC live event from @PeerView @montypal @tiansterzhang #IKCSNA24 #MedEd
Source: lrn.peerview.comCategories: General Medicine News, Hem/OncsTweet-
RT @QianJanieQin: Join us in person or #virtually at https://t.co/y0V8wz4fkY for a lively discussion with @TiansterZhang #Dr. Nazar Tannir…
-
-
Mashup Score: 1Qian Qin: Tian Zhang with kidney trial updates at Alliance for Clinical Trials in Oncology Fall 24 meeting - OncoDaily - 4 month(s) ago
Qian Qin: Tian Zhang with kidney trial updates at Alliance for Clinical Trials in Oncology Fall 24 meeting / Alliance for Clinical Trials in Oncology, cancer,
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet-
RT @oncodaily: Dr. @TiansterZhang with kidney trial updates at @ALLIANCE_org Fall 24 meeting - @QianJanieQin https://t.co/uBUYpM3fwS #Ca…
-
-
Mashup Score: 12Defining Disease Burden and Cure - 6 month(s) ago
Share your voice and help improve care for all kidney cancer patients!
Source: www.surveymonkey.comCategories: General Medicine News, Hem/OncsTweet-
Calling all patients w #kidneycancer and their amazing caregivers! Take this survey from @kcCURE & help us understand perceptions of disease burden and — dare we say! — what cure means to you. https://t.co/oOON5VC0IW @LauraEsfeller @kaydaustin @RCCadvocate https://t.co/FkG8lhMTRn
-
-
Mashup Score: 44Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer | NEJM - 6 month(s) ago
Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve…
Source: www.nejm.orgCategories: General Medicine News, UrologyTweet-
@tompowles1 presents #NIAGARA trial - first in #bladdercancer to show IO benefit for neoadjuvant durvalumab-chemo -- improved event free survival and overall survival. Concurrent @NEJM publication today! https://t.co/PmvdyWD5Oc @myESMO @OncoAlert #ESMO24 #ESMOAmbassadors https://t.co/AYxMFiuzy5
-
-
Mashup Score: 44Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer | NEJM - 6 month(s) ago
Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve…
Source: www.nejm.orgCategories: General Medicine News, UrologyTweet-
@tompowles1 presents #NIAGARA trial - first in #bladdercancer to show IO benefit for neoadjuvant durvalumab-chemo -- improved event free survival and overall survival. Concurrent @NEJM publication today! https://t.co/PmvdyWD5Oc @myESMO @OncoAlert #ESMO24 #ESMOAmbassadors https://t.co/AYxMFiuzy5
-
-
Mashup Score: 33
These data further support that ICI rechallenge should be discouraged in patients with advanced renal cell carcinoma. Furthermore, these data suggest that tivozanib monotherapy has efficacy in the post-ICI setting.
Source: www.thelancet.comCategories: General Medicine News, UrologyTweet-
@DrChoueiri presents #TiNivo2 showing no benefit of combination in IO-refractory #kidneycancer — supports tivozanib 1.34mg monotherapy. Results published in @TheLancet today https://t.co/DPQ3LvY1zP #ESMO24 @myESMO #ESMOAmbassadors https://t.co/MJVAArbP5b
-
-
Mashup Score: 33
These data further support that ICI rechallenge should be discouraged in patients with advanced renal cell carcinoma. Furthermore, these data suggest that tivozanib monotherapy has efficacy in the post-ICI setting.
Source: www.thelancet.comCategories: General Medicine News, UrologyTweet-
@DrChoueiri presents #TiNivo2 showing no benefit of combination in IO-refractory #kidneycancer — supports tivozanib 1.34mg monotherapy. Results published in @TheLancet today https://t.co/DPQ3LvY1zP #ESMO24 @myESMO #ESMOAmbassadors https://t.co/MJVAArbP5b
-
@DrChoueiri presents #TiNivo2 showing no benefit of combination in IO-refractory #kidneycancer — supports tivozanib 1.34mg monotherapy. Results published in @TheLancet today https://t.co/DPQ3LvY1zP #ESMO24 @myESMO #ESMOAmbassadors https://t.co/MJVAArbP5b